Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers by Kamalapuram, Sishir K et al.
  
 
 
 
Kamalapuram, Sishir K, Kanwar, Rupinder K, Roy, Kislay, Chaudhary, Rajneesh, Sehgal, Rakesh and Kanwar, 
Jagat R 2016, Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-
loaded novel nanocapsules in cancers, International journal of nanomedicine, vol. 11, pp. 1349-1366. 
 
DOI: 10.2147/IJN.S95253 
 
 
 
 
 
This is the published version. 
 
©2016, The Authors 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Non-Commercial 
Licence 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30085769 
 
 
 
© 2016 Kamalapuram et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of Nanomedicine 2016:11 1349–1366
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1349
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S95253
Theranostic multimodular potential of zinc-doped 
ferrite-saturated metal-binding protein-loaded 
novel nanocapsules in cancers
sishir K Kamalapuram1
rupinder K Kanwar1
Kislay roy1
rajneesh chaudhary1
rakesh sehgal2
Jagat r Kanwar1
1Nanomedicine laboratory of 
Immunology and Molecular 
Biomedical research, school of 
Medicine, centre for Molecular and 
Medical research, Faculty of health, 
Deakin University, geelong, VIc, 
australia; 2Department of Medical 
Parasitology, Postgraduate Institute 
of Medical education and research, 
chandigarh, India
Abstract: The present study successfully developed orally deliverable multimodular zinc (Zn) 
iron oxide (Fe
3
O
4
)-saturated bovine lactoferrin (bLf)-loaded polymeric nanocapsules (NCs), 
and evaluated their theranostic potential (antitumor efficacy, magnetophotothermal efficacy 
and imaging capability) in an in vivo human xenograft CpG-island methylator phenotype 
(CIMP)-1+/CIMP2−/chromosome instability-positive colonic adenocarcinoma (Caco2) and 
claudin-low, triple-negative (ER−/PR−/HER2−; MDA-MB-231) breast cancer model. Mice fed 
orally on the Zn-Fe-bLf NC diet showed downregulation in tumor volume and complete regres-
sion in tumor volume after 45 days of feeding. In human xenograft colon cancer, vehicle-control 
NC diet-group (n=5) mice showed a tumor volume of 52.28±11.55 mm3, and Zn-Fe-bLf NC diet 
(n=5)-treated mice had a tumor-volume of 0.10±0.073 mm3. In the human xenograft breast cancer 
model, Zn-Fe-bLf NC diet (n=5)-treated mice showed a tumor volume of 0.051±0.062 mm3 
within 40 days of feeding. Live mouse imaging conducted by near-infrared fluorescence imaging 
of Zn-Fe-bLf NCs showed tumor site-specific localization and regression of colon and breast 
tumor volume. Ex vivo fluorescence-imaging analysis of the vital organs of mice exhibited 
sparse localization patterns of Zn-Fe-bLf NCs and also confirmed tumor-specific selective 
localization patterns of Zn-Fe-bLf NCs. Dual imaging using magnetic resonance imaging and 
computerized tomography scans revealed an unprecedented theranostic ability of the Zn-Fe-bLf 
NCs. These observations warrant consideration of multimodular Zn-Fe-bLf NCs for real-time 
cancer imaging and simultaneous cancer-targeted therapy.
Keywords: theranostic, multimodular cancer therapy, nanocapsules, nanomedicine, real-time 
imaging
Introduction
Therapeutics derived from natural products are safe, highly biocompatible, and exhibit 
negligible toxicity. Due to these characteristics, cancer researchers are in search of 
novel noble therapeutic compounds as nanotheranostic platforms for cancer.1 Cancer 
has evolved as an increasingly complex disease, due to the innumerable cancer-growth 
mechanisms escaping the normal growth patterns that lead to severe disease states.2 
Due to these growth trends, it is very difficult for conventional chemotherapeutic 
drugs and traditional therapeutic platforms to achieve effective treatment of cancers.3–5 
Iron-saturated bovine lactoferrin (Fe-bLf) has been extensively studied for its promi-
nent ability in helping the immune system to combat cancer and also in generation of 
immune cells, such as B lymphocytes, increasing antitumor macrophage activity, and 
increased production of wide range of interleukins.3,6–9 Fe-bLf-derived nanotherapeutics 
exhibit apoptotic signaling mechanisms, and further Fe-bLf had a crucial role in the 
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modulation of key stem cell-signaling mechanisms, including 
inhibiting survivin expression and EpCAM signaling, and 
other noteworthy observations included downregulation of 
the prominent stem cell markers CD44, CD133, and CD166.8 
Interestingly, Fe-bLf nanocarriers/nanocapsules (NCs) 
exploited several internalization receptors, such as LRP1 
and -2, TfRs, and DMT1 iron-metabolism receptors.8,10
Cancer nanotheranostics is an ultramodern field that offers 
mouthwatering approaches in effective targeting of cancer 
by a three-way integrated approach: diagnostic, therapeutic, 
and monitoring of the disease condition. Due to its lucrative 
benefits, cancer nanotheranostic approaches and preferably 
eco-friendly natural product-derived compounds are in the 
limelight of research.11 In consideration of the importance of 
the multimodular nanotheranostic drug-delivery systems for 
cancer treatment, in terms of selective timely drug delivery 
at the tumor site and also real-time monitoring of disease 
conditions and cancer therapy,12 there is an urgent need for 
such agents in cancer diagnosis and therapy.
The strategy used to obtain maximum possible mag-
netization with a considerably reduced toxicity with less 
contrast agent consists of doping the ferrite-nanoparticle 
core of the employed nanocomplex. In order to achieve this 
goal, the spinel structure of the ferrite-nanoparticle core 
can be doped with metallic cations, such as copper, cobalt, 
manganese, and zinc, in order to enhance their effective 
saturation-magnetization value. The US Food and Drug 
Administration has published a daily value for intake of the 
micronutrients zinc and iron to be 15 and 18 mg, respectively, 
considerably higher than the daily value for manganese and 
cobalt at 2 mg.13 Moreover, replacement of iron with zinc 
will additionally reduce the chances of iron overloading by 
replacing ferrous ions with zinc cations. Therefore, using 
zinc as a dopant is a much safer approach to enhance the 
saturation-magnetization value of ferrite nanoparticles than 
manganese, copper, or nickel.
The present study is the first attempt to develop multi-
modular Zn-doped iron oxide (Fe
3
O
4
)-saturated bLf-loaded 
polymeric NCs (Zn-Fe-bLf NCs) for theranostic application 
in cancer therapy and imaging. Research conducted on zinc 
absorption has shown an increased correlation of anticancer 
activity with respect to zinc levels in the body. Therefore, 
increased zinc levels help in inhibiting cancer growth-
signaling mechanisms.14 Further, zinc as a micronutrient 
enhances immune-system activity in retaliation against tumor 
growth. Zinc has been classified as an important element 
for the human body as a micronutrient, and also helps in 
immunosignaling mechanisms, enriching the body’s ability 
to fight against diseases.14 Therefore, we utilized a Zn-Fe-bLf 
nanoformulation for examining its anticancer ability and also 
imaging ability in vivo.
Microsatellite-stable (MSS), chromosome instability 
(CIN)+, CpG-island methylator phenotype (CIMP)-1+/
CIMP2−/CIN+ colonic adenocarcinoma15–17 and claudin-low, 
triple-negative (ER−/PR−/HER2−) breast carcinoma10 are the 
most widespread cancers expressing specialized molecular 
characteristics, which enable them to promote tumor pro-
gression and therapeutic resistance.18–20 Current therapeutic 
approaches include the use of inhibitors for triple-negative 
breast cancer: P7170 (synthetic inhibitor), PP2A-B55β, 
IL15RA for CIMP1+/CIMP2−/CIN+ colonic adenocarcinoma, 
and the DNA methyltransferase inhibitor 5-azacitidine and 
the histone deacetylase inhibitor AR-42.15–17
In the present study, Zn-Fe-bLf NCs showed enhanced 
anticancer efficacy in the in vivo human xenograft CIMP1+ 
CIMP2−/CIN+ colonic adenocarcinoma and claudin-low, 
triple-negative breast cancer model and near-infrared (NIR) 
fluorescence imaging enabled real-time monitoring of drug 
localization at the tumor site. The multimodular imaging 
capability employing dual-mode imaging strategies, such 
as magnetic resonance imaging (MRI) and computed tomo-
graphy (CT), imparted to these NCs by the crucial zinc- and 
iron-based composition provides it an upper hand when 
compared to other currently available theranostic agents. 
Therefore, multimodular Zn-Fe-bLf NCs warrant future 
improvised extensive in vivo studies and clinical studies 
toward the development of effective nanotheranostic systems 
for cancer treatment.12
Materials and methods
CIN+, microsatellite-stable, CIMP1+, CIMP2− colon cancer 
(Caco2) and claudin-low, triple-negative (ER−/PR−/HER2−) 
breast cancer (MDA-MB-231) cell lines were purchased 
from the American Type Culture Collection (Manassas, VA, 
USA). Chitosan (20–200 cP, low molecular weight), sodium 
triphosphate, 0.25% trypsin–ethylenediaminetetraacetic 
acid (EDTA), penicillin–streptomycin, sodium alginate, 
and calcium chloride were obtained from Sigma-Aldrich 
Co (St Louis, MO, USA). Human cancer cell-culture essen-
tials were purchased from GE Healthcare and BD Biosci-
ences. A VivoTag XL fluorescent tag was obtained from 
PerkinElmer Inc (Waltham, MA, USA). Vector mounting 
media and a horseradish peroxidase-conjugate kit were 
purchased from Vector Laboratories, (Burlingame, CA, 
USA). Crystal violet stain was obtained from Thermo Fisher 
Scientific (Waltham, MA, USA).
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Fabrication of alginate-coated chitosan 
nanogel-encapsulated zinc Fe3O4-
saturated bovine lactoferrin nanocapsules
The fabrication of Zn-Fe-bLf NCs was carried out accord-
ing to previous methods with slight modifications.7,8,12 
Briefly, a 1:3 ratio of the 250 mM zinc ferrite (Zn
x
Fe
3–x
O
4
) 
and 600 mM of nitrilotriacetic acid (NTA) disodium salt 
(molecular weight 235.10) were dissolved in sterile water. 
Further, pH was adjusted to 7. Later, 0.1 M solid sodium 
bicarbonate was added to 0.1% solution of apo-bLf and 
pH adjusted to 8. Then, the freshly prepared Zn-Fe-NTA 
solution was added dropwise to prepared apo-bLf solution 
while magnetically stirring the solution. In the presence of 
carbonate ions, structural confirmation of the Lf molecule 
possessing iron-binding pockets initiates the uptake of iron 
molecules.
The Zn-Fe-NTA solution was added to the protein solu-
tion until a reddish black-brown color solution was formed. 
This color formation signifies the 100% iron saturation of 
Lf. Further, the obtained mixture was subjected to overnight 
magnetic stirring at 4°C in order to stabilize the Zn-Fe-bLf 
complex. Later on, the Zn-Fe-bLf solution was separated by 
centrifugation techniques at 5,000 rpm for 10 minutes. The 
obtained Zn-Fe-bLf formulation was thoroughly washed with 
sterile phosphate-buffered saline (PBS). Further, the obtained 
Zn-Fe-bLf was coated with a chitosan-nanogel layer (0.1% 
w/w) in the presence of sodium triphosphate added dropwise, 
while magnetically stirring the solution. Later, the mixture 
was subjected to overnight magnetic stirring, followed by col-
lection of the nanoformulation by centrifugation and thorough 
washing with sterile PBS. Zn-Fe-bLf NCs were coated with 
alginate gel (0.1% w/w) in the presence of calcium chloride 
(CaCl
2
) solution added dropwise while magnetically stirring 
the solution. The mixture was then subjected to 6 hours’ 
magnetic stirring, and later Zn-Fe-bLf NCs were separated 
by centrifugation techniques and washed with sterile PBS. 
Void NCs lacked the Lf component in them. 
Fluorescent Zn-Fe-bLf NCs were fabricated by conjuga-
tion of the VivoTag XL fluorophore tag onto the chitosan 
layer, and stable amide linkages were formed between the 
succinimidyl ester (present on the fluorophore) and amine 
group (present on the chitosan layer). Later, fluorescent NCs 
were subjected to thorough purification by chromatographic 
purification column, in order to remove unbound fluoro-
phore molecules from the already formed fluorescent NCs. 
Alginate-coated chitosan nanogel-encapsulated Zn-Fe-bLf 
NCs were obtained, and lyophilization of samples was carried 
out and utilized for further research studies. The ζ-potential 
for the NCs was found to be −1.29 and the size 322±17 nm, 
due to the outer coating of alginate, with the help of a Malvern 
Zetasizer Nano ZS.
characterization of zinc-doped ferrite 
particles
Hysteresis-loop measurement for Zn-Fe nanoparticles 
per unit weight under an applied magnetic field was done 
using a Quantum Design PPMS AC/DC 1.8–400 K, 0–9 T, 
0–3,000 Hz magnetometer at 273 K. A Panalytical X’Pert® 
Pro MRD XL X-ray diffractometer was used for assessment 
of spinel Zn-Fe
3
O
4
 crystallographic structure. Freeze-dried 
nanoparticle powder was placed in the sample holder, 
and the top layer was smoothened prior to the scan. The 
sample holder was fixed into the target slot, and a z-axis 
scan position was manually adjusted while a 0.2 μm-thick 
copper attenuator was placed at the X-ray generator end. 
The scan angle was specified from 25° to 75° 2θ X-ray 
beam angle, and the scan parameters as 0.02-unit step 
size per 2 seconds. Scan-intensity values were obtained 
in CSV format and the plot reconstructed using Microsoft 
Excel software. Size and surface morphology of Zn-Fe
3
O
4
 
nanoparticles were assessed by JEOL JEM-2100 LaB6 
transmission electron microscope. Samples were prepared 
on carbon-coated 400-mesh GSCU400C-50 Formvar cop-
per grids, and standard operating protocol was followed 
with constant 200 kV high-tension voltage and 110 μA 
beam current. Size and surface morphology of Zn-Fe
3
O
4
 
nanoparticles were reevaluated using a Zeiss Supra™ 55VP 
FEG scanning electron microscope with Gemini® column. 
Imaging samples were prepared on a double-sided carbon 
tape on a 12 mm-diameter metallic stub sample holder and 
marked for identification, and standard instrument-operating 
protocol was followed.
In vitro human tissue-culture analysis for 
Zn-Fe-blf Ncs in cancer cells
cell-culture conditions
Human cancer cell culture was carried out as a monolayer 
culture with Leibovitz media (L-15) without CO
2
 for triple-
negative breast cancer cells (MDA-MB-231), Dulbecco’s 
Modified Eagle’s Medium for colonic adenocarcinoma 
cells (Caco2) and 10% fetal bovine serum, and penicillin 
(20 units/mL) and streptomycin (20 mg/mL) (all Thermo 
Fisher Scientific) antibiotic solution were added as growth 
supplements. Trypsinization (with 0.25% trypsin–EDTA for 
3–5 minutes) of cancer cells was carried at a cell confluence 
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of 80%–90%. Cancer cells were cultured at 37°C in 25 cm2 
and 75 cm2 flasks.
Tumor-cell internalization studies for Zn-Fe-blf Ncs
Immunocytochemistry was carried out to determine the 
cellular internalization efficiency of Zn-Fe-bLf NCs in 
breast cancer cells. Multiwell chamber slides were utilized 
to culture the cells (concentration 103 cells/well). Treatment 
concentrations of 125 μg/mL of Zn-Fe-bLf NCs along with 
an equivalent concentration of void NCs were carried out on 
the cells for 24 hours. Later, NC treatments were removed and 
cells rinsed thoroughly with sterile PBS. Freshly prepared 4% 
paraformaldehyde was utilized for fixation of cells for about 
20 minutes. Rinsing of cell layers was carried out with sterile 
PBS. Cell permeabilization was carried out for 2 minutes with 
0.1% Triton X. Later, cell layers were rinsed with sterile PBS. 
Further, an immunoperoxidase kit (Vector Laboratories) was 
utilized for immunocytochemistry analysis. Firstly, a blocking 
step was performed for 1 hour with 1% porcine gelatin. Next, 
cell layers were rinsed with sterile PBS followed by antibody 
incubations. Primary antibody incubation was performed 
with goat anti-bLf (Bethyl Laboratories, Montgomery, TX, 
USA) with a dilution ratio of 1:200 for 1 hour at 37°C. Later, 
the primary antibody incubation was removed and cell lay-
ers rinsed with sterile PBS. Secondary antibody incubation 
was carried out with an antigoat peroxidase HRP-conjugate 
kit with a dilution ratio of 1:200 for 1 hour at 37°C. Later, 
cell layers were thoroughly rinsed with sterile PBS and 
diaminobenzyl substrate (Sigma-Aldrich) was incubated for 
10 minutes. Propidium iodide (1%) staining of nuclei was 
performed in the dark. Later, cell layers were rinsed with 
sterile PBS. Further, mounting of slides was carried out and 
imaging performed by a Zeiss inverted microscope.
Zn-Fe-blf Nc response for tumor colony-formation 
efficiency
Clonogenic tumor-formation assays were performed as per 
the following protocol. Cancer cells were seeded in a six-
well plate at a concentration of 106 and allowed to grow till 
cells reach confluence. Next, Zn-Fe-bLf NC treatment cor-
responding to protein concentrations of 400 and 800 μg/mL 
and void NCs (equivalent to 800 μg/mL) were incubated 
with the cells for 24 hours. Later, treatments were removed 
from cell layers and rinsing of cells with sterile PBS was 
performed. Next, approximately 300 cells from each well 
were transferred to 1% (w/v) agarose coated six-well plates. 
Further, tumor cells were allowed to grow for 12 days. Then, 
colony formation was noted from the second day of cell 
seeding, and colony growth was monitored. After 12 days 
of incubation, fixation of colonies was performed with 4% 
paraformaldehyde. Later, crystal violet (1%) staining of 
colonies was performed. Further, colonies were counted by 
utilization of a colony-counter number in the control. Void 
NC- and Zn-Fe-bLf NC treatments and colony-formation 
efficiency were represented in a histogram.
In vivo nude mice (BalB/c nu/nu) studies 
to evaluate antitumor efficacy of Zn-Fe-
blf Ncs in human xenograft cIMP1+/
cIMP2−/cIN+ colonic adenocarcinoma 
and claudin-low, triple-negative (er−/Pr−/
her2−) breast cancer model
In vivo nude mouse studies were performed to assess the 
anticancer ability in human xenograft CIMP1+/CIMP2−/CIN+ 
colonic adenocarcinoma and claudin-low, triple-negative (ER−/
PR−/HER2−) breast cancer models by oral administration of Zn-
Fe-bLf NCs in the diet. The study was performed as per Deakin 
University, Australia (animal ethics committee approval 
no: A91 - 2010), KU-Warangal, India (IAEC/22/a/UCPSc/
KU/2013), and Postgraduate Institute of Medical Education 
and Research, India (IAEC no: 47/1999/CPCSEA) animal 
ethics regulations. A C57 BALB/c nu/nu nude mouse model 
was employed to develop human xenograft colon (Caco2) and 
breast (MDA-MB-231) cancer.7,10 An AIN-93G diet (Specialty 
Feeds, Perth, Australia) mixed with 1.2% w/w of Zn-Fe-bLf 
NCs was utilized for oral cancer therapy in the form of pellets. 
The study was approved by the ethics committee of Deakin 
University (animal ethics committee approval no: A91 - 2010), 
PGIMER-Chandigarh (IAEC no: 47/1999/CPCSEA) and KU-
Warangal (IAEC/22/a/UCPSc/KU/2013/).
AIN-93G includes fat, fiber elements, vitamins, carbo-
hydrates, and protein. The diet is free from casein (milk 
component), in order to nullify the therapeutic adjuvant 
effect of casein. The components of AIN-93G are barley, 
soybean meal, mixed vegetable oils, salt, canola oil, wheat, 
calcium carbonate, magnesium oxide, dicalcium phosphate, 
trace minerals, and vitamins.
human xenograft colon cancer studies
Eight-week-old athymic mice were subcutaneously injected 
with the Caco2 tumor cell line (107 cells/each mouse) and 
MDA-MB-231 cells (106 cells/each mouse). (Colon cancer 
studies, vehicle-control NC-diet group [n=5] and Zn-Fe-bLf 
NC-diet group [n=5]; breast cancer studies, vehicle-control 
NC-diet group [n=5] and Zn-Fe-bLf NC-diet group [n=5]).
Later, after a tumor-volume range of 50–60 mm3 was 
reached, oral administration of the NC diet was carried 
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out. Routine monitoring of mouse weight, body condition, 
and behavior was performed. Tumor-volume monitoring 
was carried out with Vernier calipers and calculated by the 
formula tumor volume (mm3) =0.5× L × W2, where L is length 
(longest tumor dimension) and W is width (shortest tumor 
dimension). The study was conducted for 90 days, and later 
vital organs were collected after the mice were killed. Mouse 
tissues were processed and stored in appropriate media for 
future work.
Magnetophotothermal therapy
In vivo human xenograft colon and breast magnetophoto-
thermal therapy was carried out. The following mouse tumor 
models were studied: control diet – colon (n=5) and breast 
(n=5), control diet colon + magnetic scratch + photothermal 
therapy (n=5); Zn-Fe-bLf NC diet, colon tumor + magnetic 
scratch + photothermal therapy (n=5); Zn-Fe-bLf NC diet, 
breast tumor + magnetic scratch + photothermal therapy (n=5). 
Magnetic fields were applied over the tumor area twice a day, 
photothermal lasers were applied at the tumor site around three 
times a week, and tumor-mass patterns were examined.
Near-infrared fluorescence-based cancer-
imaging strategies to evaluate antitumor 
efficacy of Zn-Fe-bLf NCs in human 
xenograft cIMP1+/cIMP2−/cIN+ colonic 
adenocarcinoma and claudin-low, triple-
negative (er−/Pr−/her2−) breast cancer
NIR-fluorescence imaging was carried out with the IVIS-2 
Lumina imaging system. Live mouse NIR-fluorescence 
imaging was conducted by anesthetizing mice for a short 
time period. Fluorescent Zn-Fe-bLf NCs were detected by 
the fluorescent signal of the tag in the wavelength range 
(675–740 nm), and fluorescent photographs were obtained. 
The obtained mouse images were analyzed to determine the 
localization and biodistribution patterns of Zn-Fe-bLf NCs 
in the body. The fluorescent signal obtained at the tumor 
site was quantified to assess the tumor-regression trend in 
terms of average radiant efficiency ([p/s/cm2/sr]/[μW/cm2]) 
and area of fluorescent signal at the tumor site. Furthermore, 
ex vivo mouse organ-imaging analysis was conducted to 
assess the biodistribution patterns (in terms of average radiant 
efficiency) of Zn-Fe-bLf NCs in mouse tissues.
In vivo magnetic resonance imaging and 
computerized tomography analysis
Mice were subcutaneously injected with 106 Caco2 cells, 
and tumors were allowed to develop in mice. Once tumors 
were developed, commercially available MRI contrast 
agent (Magnevist) and bLf (1.6 mg/mL) were injected 
intratumorally. Another set of mice were fed with Fe-bLf NCs 
(1.2% w/w), and Zn-Fe-bLf NCs (1.2% w/w) for 48 hours. 
Untreated mice were maintained as control. Both the T
1
 and 
T
2
 MRI signal intensities of Magnevist, bLf, Fe-bLf NCs, 
Zn-Fe-bLf NCs were measured immediately after injection 
of the MRI agents using Q-engine (33 mT/m at 125 T/m/s) 
from Siemens (1.5 T) with a magnet weight of 3,550 kg and 
a 10 MHz signal rate with resolution of 100 nanoseconds. 
The CT scans were obtained using the Somatom CT scan-
ner (Siemens Australia) at the Monash Biomedical Imaging 
Centre, Melbourne. Mice were anesthetized with isoflurane 
for these studies.
estimation of iron, calcium, and zinc
Serum iron concentrations were determined using a previ-
ously published procedure,6 whereas serum calcium concen-
trations were determined using a fura-2-acetoxymethyl ester 
as previously published.12,21 Serum zinc concentration was 
determined using atomic absorption spectrophotometry.22
statistical analysis
Statistical analysis was performed with Student’s t-test 
(unpaired) using online GraphPad software on the triplicate 
data generated from individual or triplicate experiments. 
P,0.05 denoted statistical significance, whereas P,0.01 
denoted results that were highly significant, and P,0.001 
denoted results that were very highly significant.
Results and discussion
The studies were performed to delineate the multifunctional 
anticancer nature of novel Zn-Fe-bLf NCs and also to 
uncover their multimodular property in terms of real-time 
cancer imaging and therapy.23,24 Earlier studies conducted 
with Fe-bLf NCs nanotherapeutics showed a multifunc-
tional nature in terms of modulation of critical anticancer-
signaling nodes, boosting the immunosignaling mechanism 
by enriching the production of B cells, natural killer cells, 
and interleukin expression. Furthermore, Fe-bLf and Fe-bLf 
nanoformulations showed increased cytokine expression, 
promoting macrophage and phagocytic activity.7,8,25 Fe-bLf 
nanoformulations were noted to play a crucial role in mediat-
ing anticancer signaling through the cancer stem cell-signal-
ing mechanism. Experimental investigations were conducted 
with Fe-bLf in combination with chemotherapeutic regimes, 
such as Taxol. Recent research findings revealed improvised 
antitumor ability of Fe-bLf in in vivo colon and breast cancer 
models.7,8,10 Further, recent studies conducted with polymeric 
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Fe-bLf NC nanoformulations proved antitumor mechanisms 
of Fe-bLf in the stem cells.8 However, no attempt has been 
made so far to saturate bLf with Zn-Fe
3
O
4
. The zinc doping 
was performed in order to provide a theranostic edge to this 
conjugate. Earlier studies relating to zinc expression and 
absorption patterns revealed its role in boosting the anti-
cancer response in correlation with therapeutic regimes. An 
important micronutrient, zinc also plays a key role in boosting 
immune responses and helps in fighting against disease-state 
conditions.13,26 In consideration of the importance of zinc in 
relation to its therapeutic ability, Zn-Fe-bLf NCs were studied 
to understand their combinatorial anticancer activity. The 
current work enabled examination of novel multifunctional 
and multimodular Zn-Fe-bLf NCs for their anticancer ability 
in in vivo human xenograft CIMP1+/CIMP2−/CIN+ colonic 
adenocarcinoma and claudin-low, triple-negative (ER−/PR−/
HER2−) breast cancer models. Further, the multimodular 
nature of the nanoformulation was delineated by laser-based 
NIR imaging, MRI, magnetophotothermal imaging, and 
positron-emission CT therapeutic imaging.
synthesis and characterization of 
superparamagnetic zinc-doped ferrite 
particles and Zn-Fe-blf Ncs
Ferrite nanoparticles were synthesized with controlled con-
centration of zinc (Zn
x
Fe
3–x
O
4
) by chemical coprecipitation 
followed by hydrothermal treatment. Superparamagnetism 
was typically displayed with maximum saturation magneti-
zation of zinc-doped ferrite nanoparticles (Zn
0.4
Fe
2.6
O
4
) at a 
value of 109.8 emu/g observed by semiconductor quantum 
interference-device measurement at 273 K temperature, 
which would lead to highly effective T
2
 relaxation MRI 
contrast (Figure 1A). High-resolution images obtained using 
transmission electron microscopy revealed a smooth spheri-
cal morphology of the synthesized nanoparticles, with an 
average diameter of 24±2.8 nm (Figure 1B). The formation 
of zinc-doped ferrite nanoparticles was confirmed by assess-
ment of crystallographic orientation X-ray diffractometric 
analysis using the Panalytical X-pert powder X-ray diffrac-
tometer (Figure 1C). The size and surface morphology of the 
nanoparticles was reconfirmed to be smooth and spherical 
by scanning electron microscopy (Figure 1D).
In vitro human tissue-culture analysis for 
Zn-Fe-blf Ncs in cancer cells
Tumor-cell internalization studies for Zn-Fe-blf Ncs
Immunocytochemistry-based detection of Fe-bLf was 
clearly observed, as shown in Figure 1E. The brown color is 
representative of the specific reaction of Lf antibodies with 
Zn-Fe-bLf NCs internalized in the MDA-MB-231 cell line. 
The observations noted in cellular internalization of Zn-Fe-
bLf NCs in claudin-low, triple-negative (ER−/PR−/HER2−) 
breast cancer cells (MDA-MB-231) was performed by 
immunocytochemistry-based detection, and the results con-
clusively showed remarkable internalization efficiency of 
Zn-Fe-bLf NCs within 2 hours compared to the void NCs 
(Figure 1E).
Zn-Fe-blf Nc response for tumor colony-formation 
efficiency
Zn-Fe-bLf NCs exhibited a dose-dependent response in 
terms of colony-growth inhibition in comparison to void NCs 
and control (Figure 1F). It was observed that with varying 
treatment concentrations (400 μg/mL and 800 μg/mL) of 
Zn-Fe-bLf NCs, colony growth-inhibition efficiency was 
enhanced (Figure 1G). These observations were in accord 
with our previous findings relating to remarkable colony 
growth-inhibition ability of Fe-bLf by modulating crucial 
cell-signaling pathways, including STAT, VEGF, EGFR, 
and FGF cell-signaling mechanisms.10,27
evaluation of in vivo antitumor 
efficacy of Zn-Fe-bLf NCs in human 
xenograft cIMP1+/cIMP2−/cIN+ colonic 
adenocarcinoma and claudin-low, triple-
negative (er−/Pr−/her2−) breast cancer
Studies were conducted to examine the in vivo antitumor 
efficacy of vehicle-control NCs and Zn-Fe-bLf NCs in 
human xenograft CIMP1+/CIMP2−/CIN+ colonic adenocar-
cinoma and claudin-low, triple-negative (ER−/PR−/HER2−) 
breast cancer. Routine monitoring of tumor volumes was 
carried out.
Tumor-volume monitoring in human xenograft colon 
cancer
The vehicle-control NC-diet group (n=5) showed a tumor 
volume of 52.28±11.55 mm3, the control group (n=5) 
93.51±5.26 mm3, and the Zn-Fe-bLf NC-diet group (n=5) 
0.10±0.073 mm3. Time-dependent and reduction patterns in 
tumor volume were noted in Zn-Fe-bLf NC-diet mice when 
compared to the vehicle-control NC-diet group. The Zn-
Fe-bLf NC-diet treatment was started around day 42, after 
appropriate tumor size had been reached. Once the mice 
were fed the Zn-Fe-bLf NC diet, it led to downregulation 
of tumor volume. The mice were fed the diet continuously 
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till day 90, and complete regression in tumor volume was 
observed (Figure 2A). In conclusion, Zn-Fe-bLf NCs showed 
the potential to be used as an anticancer therapeutic for colon 
cancer. Collectively, Zn-Fe-bLf NCs exhibited consistent 
antitumor efficacy and a nontoxic and biocompatible nature 
in the colon cancer model.
Tumor-volume monitoring in human xenograft breast 
cancer
The control group (n=5) showed a tumor volume of 
70.59±3.75 mm3, the vehicle-control NC-diet group (n=5) 
57.05±3.33 mm3, and the Zn-Fe-bLf NC-diet group (n=5) 
0.051±0.062 mm3. These observations conclusively establish 
Figure 2 Anticancer efficacy of Zn-Fe-bLf in human xenograft CIMP1+/cIMP2−/cIN+ colonic adenocarcinoma and claudin-low, triple-negative (er−/Pr−/her2−) breast cancer 
model.
Notes: (A) Nanoformulated diet was given to mice at 50–60 mm3 tumor-volume range, around day 42. colon cancer model: vehicle-control Nc-diet group (n=5) showed a 
tumor-volume of 52.28±11.55 mm3, with the control group (n=5) 93.51±5.26 mm3. an increasing trend in tumor volume was observed. The Zn-Fe-blf Nc-diet group (n=5) 
showed a tumor-volume of 0.10±0.073 mm3. a regression trend in tumor volume was observed in Zn-Fe-blf Nc-treated mice in comparison to the vehicle-control group. 
Breast cancer model: tumor volume monitoring was carried out as represented in the chart. The Zn-Fe-blf nanoformulated diet was given to mice within a 50–60 mm3 tumor-
volume range, around day 60. The Zn-Fe-blf Nc-diet group (n=5) showed a tumor-volume of 0.051±0.062 mm3, the vehicle-control Nc-diet group (n=5) 57.05±3.33 mm3, 
and the control group (n=5) 70.59±3.75 mm3. a regression trend in tumor volume was observed in Zn-Fe-blf Nc-treated mice. results presented as mean ± seM. (B) colon 
cancer: mouse body weight was routinely monitored, as shown in the chart. The vehicle-control Nc-diet group (n=5) showed a weight of 21.32±1.45 g, and the Zn-Fe-blf Nc-
diet group (n=5) showed a weight of 21.36±0.71 g. a consistent increasing trend in weight was observed. Breast cancer: the Zn-Fe-blf Nc-diet group (n=5) showed a weight of 
20.64±1.64 g, with the vehicle-control Nc-diet group (n=5) 21.27±1.19 g. a consistent increasing trend in weight was observed. results presented as mean ± seM. (C) Zn-Fe-
blf Nc-diet administration was carried out around day 60 for colon and breast xenograft tumor mice. an increment in tumor growth was observed in the control diet (colon 
tumor, breast tumor, and colon tumor + magnetic scratch + photothermal therapy), while the Zn-Fe-blf Nc diet (colon tumor + magnetic scratch + photothermal therapy and 
breast tumor + magnetic scratch + photothermal therapy) showed enhanced tumor reduction. results presented as mean ± seM. (D) excised mouse organs were subjected to 
weight analysis, and all organs listed in the figure showed optimal weight patterns in the vehicle-control NC-diet group (n=5), the Zn-Fe-blf Nc-diet colon cancer model (n=5), 
and the Zn-Fe-blf Nc-diet breast cancer model (n=5). results presented as mean ± seM. *P,0.05 denotes significant value and **P,0.01 denotes a highly significant value.
Abbreviations: blf, bovine lactoferrin; cIMP, cpg-island methylator phenotype; cIN, chromosome instability; Nc, nanocapsule; seM, standard error of mean.
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the remarkable ability of Zn-Fe-bLf NCs in downgrading 
the tumor. Antitumor-response assessment of the Zn-Fe-bLf 
NCs in the human xenograft breast cancer model showed 
remarkable tumor downgrading ability, causing tumor 
regression (Figure 2A). Oral administration of NCs was 
started around day 60 and continued till day 90. The Zn-
Fe-bLf NC-treatment group exhibited a tumor volume of 
0.051±0.062 mm3. In summary, these observations showed 
improved antitumor response of Zn-Fe-bLf NCs. Therefore, 
Zn-Fe-bLf can be considered a safe multifunctional anti-
cancer agent.
Zn-Fe-bLf NC administration caused antitumor effects, 
as observed in our earlier findings with respect to Fe-bLf 
nanoformulations.8,10 The vehicle-control diet group (colon 
cancer) showed a slight reduction of initial tumor growth till 
day 10. This may be attributed to the ability of the vehicle 
control to generate free radicals and reactive oxygen spe-
cies that caused a temporary slowdown;28 however, in the 
long term an increasing trend in tumor-growth patterns was 
observed in the vehicle-control diet group. Collectively, 
these findings reveal in vivo antitumor efficacy in the human 
xenograft colon and breast cancer models. Interestingly, zinc 
absorption had a positive correlation with Fe-bLf anticancer 
function, and findings showed that Fe-bLf exhibited improved 
antitumor response in correlation with increased expression 
of intracellular zinc absorption in the blood. Therefore, the 
novel correlation observed with respect to the zinc and Fe-bLf 
function might enable the effective functioning of Zn-Fe-bLf 
NCs in promoting antitumor actions. Cellular internalization 
mechanisms of Fe-bLf have been extensively investigated, 
and are mainly promoted via LRP1 and -2, DMT1, and 
transferrin receptors.10,24,27 Absorption of zinc can also be 
promoted via zinc-specific receptors29 and DMT1.30–32 There-
fore, understanding the in vivo internalization mechanisms 
of Zn-Fe-bLf NCs is a goal for the future.
evaluation of magnetophotothermal 
effect of Zn-Fe-blf Ncs in human 
xenograft cIMP1+/cIMP2−/cIN+ colonic 
adenocarcinoma and claudin-low, triple-
negative (er−/Pr−/her2−) breast cancer
Magnetophotothermal studies in the tumor xenografts revealed 
that the control-diet group in the colon and breast cancer models 
in the presence of an applied magnetic field and photo thermal 
lasers showed incremental growth patterns in tumor mass. 
However, the Zn-Fe-bLf NC-diet colon group + an applied 
magnetic field + photothermal laser showed a tumor-reduction 
trend. Similarly, the Zn-Fe-bLf-diet breast cancer group + an 
applied magnetic field + photothermal laser exhibited down-
regulation of tumor growth (Figure 2B). These observations 
revealed that the Zn-Fe-bLf NC diet in association with an 
applied magnetic field and photothermal laser application at 
the tumor site caused successful cancer-growth inhibition in 
both the colon and breast cancer xenografts. Although mag-
netophotothermal studies have been carried out, they have 
mostly been on in vitro33 or intratumoral models.34 This is a 
noninvasive technique for cancer treatment, and the presence 
of Zn-Fe
3
O
4
 provides a superior photothermal therapeutic 
effect. The superior magnetization of zinc-doped Fe
3
O
4
 was 
found to be the reason for the substantial magnetophotother-
mal effects observed in the present study. Therefore, these 
results establish the utilization of Zn-Fe
3
O
4
 as a multimodular 
magnetophotothermal nanotheranostic agent.
evaluation of in vivo nontoxic nature 
of Zn-Fe-blf Ncs in human xenograft 
cIMP1+/cIMP2−/cIN+ colonic 
adenocarcinoma and claudin-low, triple-
negative (er−/Pr−/her2–) breast cancer
Studies were conducted to evaluate the nontoxic nature of the 
NCs. The observations included mouse-weight monitoring, 
body condition and appearance, monitoring water and diet 
intake, natural behavioral patterns, clinical signatures con-
cerning respiration, and gait movements. Oral administration 
of the Zn-Fe-bLf NC-formulated diet was carried out with 
human xenograft colon and breast cancer tumors. Zn-Fe-bLf 
NCs exhibited a completely nontoxic nature, and mice admin-
istered the Zn-Fe-bLf diet showed normal behavioral pat-
terns, normal gait movements, and an optimal weight trend, 
and in turn mice appeared healthy, showing regular intake of 
food and water. Oral administration of the nanoformulated 
diet was carried out in the form of pellets. Weights of the 
mice were routinely monitored, and a consistent increase in 
weight was observed in treatment (vehicle-control NC-diet 
group and Zn-Fe-bLf NC-diet group) models.
human xenograft colon cancer
The vehicle-control NC-diet group (n=5) showed weight 
of 21.32±1.45 g, the Zn-Fe-bLf NC-diet group (n=5) 
21.36±0.71 g.
human xenograft breast cancer
The vehicle-control NC group exhibited weight of 
21.27±1.19 g and the Zn-Fe-bLf NC-diet group (n=5) 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
2.
1.
15
3 
on
 3
0-
Au
g-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1358
Kamalapuram et al
20.64±1.46 g. These observations showed a consistent 
increase in the weight of mice throughout the study period 
(Figure 2C).
Ex vivo weight analysis was also performed to see the effect 
of the diets on individual organs, as excessive weight loss has 
been related to cytotoxicity in organs.35 Our results confirmed 
that no significant differences were observed in weights of indi-
vidual organs of mice after NC feeding. However, significant 
weight loss (P,0.05) in tumors in both colon and breast cancer 
in mice fed Zn-Fe-bLf NC diets were observed when compared 
to the mice fed the vehicle-control diet (Figure 2D). In sum-
mary, the in vivo evaluation of Zn-Fe-bLf in human xenograft 
colon and breast cancer studies proved to be absolutely non-
toxic and highly biocompatible and improved mouse health, 
giving hope for development of Zn-Fe-bLf NCs as a safe and 
nontoxic oral anticancer therapeutic.
Near-infrared fluorescence-based 
live mouse imaging strategy in human 
xenograft cIMP1+/cIMP2−/cIN+ colonic 
adenocarcinoma and claudin-low, triple-
negative (er−/Pr−/her2−) breast cancer
The multimodular nanotheranostic capability of Zn-Fe-bLf 
NCs was revealed by employing real-time NIR fluorescence-
based laser imaging. For imaging studies, the VivoTag 
680 XL (fluorochrome dye used for NIR imaging) was 
encapsulated within the chitosan–sodium triphosphate layer 
of the NCs. Imaging studies were conducted with the IVIS 
Lumina NIR fluorescence-imaging system. Selective local-
ization of the Zn-Fe-bLf NCs was observed at the tumor site 
in the human xenograft colon cancer model (Figure 3A). The 
biodistribution of NCs was also determined in mice after 
complete regression of tumors (Figure 3A).
Figure 3 Near-infrared fluorescence-based live mouse imaging in human xenograft CIMP1+/cIMP2−/cIN+ colonic adenocarcinoma model.
Notes: (A) (a) selective localization of Zn-Fe-blf Ncs at the colon cancer-tumor site. (b) regression in tumor volume after treatment of mice with Zn-Fe-blf Ncs over time. 
Arrows demarcate the location of tumour. The Zn-Fe-bLf NC-localization trend was quantified in terms of radiant efficiency to denote the antitumor efficacy of Zn-Fe-bLf NCs in 
the human xenograft colon cancer model (n=5). (B) (a) Localization of Zn-Fe-bLf NCs was noticed in tumors, stomach, spleen, kidney, and intestine. The fluorescence intensity of 
Zn-Fe-bLf NCs was represented in terms of radiant efficiency. The image is representative of the imaging analysis performed in the Zn-Fe-bLf NC-treatment group (n=5). (b) ex vivo 
black-and-white imaging of mouse organs was carried out. The image is representative of the imaging analysis performed in the Zn-Fe-blf Nc-treatment group (n=5). (C) (a) ex vivo 
fluorescence imaging of mouse organs was carried out. All mouse organs denoted showed sparse localization of Zn-Fe-bLf NCs. The image is representative of the imaging analysis 
performed in the Zn-Fe-blf Nc-treatment group (n=5). (b) ex vivo black-and-white imaging analysis of mouse organs. The image is representative of the imaging analysis performed 
in the Zn-Fe-blf Nc-treatment group (n=5). (D) Biodistribution patterns of Zn-Fe-blf Ncs in mouse organs in terms of percentage in vital organs of mice (n=5).
Abbreviations: cIMP, cpg-island methylator phenotype; cIN, chromosome instability; blf, bovine lactoferrin; Ncs, nanocapsules.
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Similar observations were made in the xenograft breast 
cancer model, where maximum localization of Zn-Fe-bLf 
NCs was found to be present in the tumor (Figure 4A), 
while in mice with complete regression of tumors the NCs 
were located elsewhere (Figure 4A). A time-dependent, 
consistent decremental pattern of tumor volume was noted, 
as observed by the in vivo NIR-fluorescence imaging of 
Zn-Fe-bLf NCs. The obtained images were quantified in 
terms of radiant efficiency, area (cm2), area (in terms of 
charge-coupled-device camera pixels) for graphical rep-
resentation of tumor reduction in the mice (Figures S1 
and S2). In our previous research, we have not noted any 
immunostimulatory effects of the vehicle control.8 However, 
in the present study (Figure 2A), it was observed that mice 
fed on the vehicle-control diet showed relatively low tumor 
volumes when compared to control mice. This could primar-
ily be due to the anticancer activity of chitosan. This is mainly 
because the nanoparticles generally accumulate at the tumor 
site due to the enhanced-permeability-and-retention effect, 
in order to induce anticancer activity.7
Collectively, these observations show the remarkable 
capability of Zn-Fe-bLf NCs for preferential localization 
at the tumor site. Zn-Fe-bLf NC localization was moni-
tored over time, and an increase in the theranostic ability 
for a longer time period was observed. Improved retention 
of Zn-Fe-bLf NCs was noted, which helped in increased 
antitumor response in the reticuloendothelial system of 
the mouse body. The Zn-Fe-bLf NCs were quantified in 
realms of radiant efficiency and area (cm2, charge-coupled 
device pixels) to denote the time-dependent antitumor 
response exhibited by Zn-Fe-bLf NCs (Figures S1 and S2). 
These novel findings reveal interesting observations of 
Zn-Fe-bLf NC multimodular antitumor activity. In sum-
mary, the multimodular imaging capacity of Zn-Fe-bLf 
NCs revealed tumor-specific localization, promising thera-
peutic activity as monitored by the NIR-imaging modality. 
Furthermore, tumor-specific drug targeting with improved 
therapeutic efficiency can be achieved by employing combi-
natorial therapeutic imaging platforms, including MRI and 
positron-emission tomography.
Tumor-specific localization and increased intestinal 
uptake of Zn-Fe-bLf NCs was significantly mediated via 
LRP, TfR, and Lf receptors, which are located on their 
surface, as observed in our earlier findings with Fe-bLf NC 
nanoformulations.8,10 In turn, iron-specific receptors, such 
as DMT1, ferroportin, and ferritin receptors, can also have 
a crucial role in absorption of Zn-Fe-bLf NCs. Zn-Fe-bLf 
NC retention was detected in the spleen, and could have 
been due to the presence of iron-specific receptors, splenic 
macrophage receptors that increasingly promote the uptake 
of Zn-Fe-bLf NCs. Kidney absorption of Zn-Fe-bLf NCs 
showed that Zn-Fe-bLf NCs are easily eliminated through 
the system without causing toxicity in the mouse body. The 
biodistribution patterns of Zn-Fe-bLf NCs in various mouse 
organs are denoted in Table 1.
Research has confirmed that zinc-internalization recep-
tors are also expressed in abundance on the tumor surface.31 
In turn, absorption of Zn-Fe-bLf NCs was observed in 
such tissues as the intestine and stomach, which obviously 
stands as a testimonial to effective oral delivery of the 
nanoformulation in the digestive system. The presence of 
polymeric coatings, such as a chitosan layering and alginate-
gel encapsulation, around the Zn-Fe-bLf protects it from the 
acidic and alkaline environmental conditions in the digestive 
system.7 Therefore, increased absorption and improved thera-
peutic retention capability in the mice body was observed. 
With respect to the absorption ability of Zn-Fe-bLf-based 
nanoformulations, these findings were conclusively in accor-
dance with our earlier published findings.7,8 Further, uptake 
of the Zn-Fe-bLf in the kidney was noted, suggesting that 
residual Zn-Fe-bLf NCs were easily eliminated via the renal 
system, helping to minimize any side effects. Interestingly, 
enhanced splenic uptake of the Zn-Fe-bLf NCs was also 
noted. This observation can be attributed to the presence 
of zinc-absorption and -internalization receptors and also 
Lf-internalization receptors on the surface of the spleen.6 
The therapeutic properties of bLf is a consequence of this 
absorption phenomenon which further includes, promoting 
anti-tumor response by increasing splenic-based immune-cell 
activity via anticancer-phagocyte and antitumor-macrophage 
activity.6,25 Furthermore, scarce biodistribution trends of 
Zn-Fe-bLf NCs were observed in the brain, eye, skin, rec-
tum, ovary, limbs, heart, lungs, bone, muscles, and liver. 
In summary, the biodistribution trends observed warrant 
tumor-specific drug delivery of Zn-Fe-bLf NCs. Zn-Fe-bLf 
NCs exhibited interesting multifunctional and multimodu-
lar ability in terms of exhibiting an anticancer nature and 
multimodular imaging, enabling monitoring of real-time 
therapeutic effects through NIR-imaging capability.
In vivo magnetic resonance imaging and 
computerized tomography analysis
The images obtained using MRI revealed that although 
the commercially available MRI contrast agent Magnevist 
(gadopentetate dimeglumine) gave a bright (T
1
) contrast at 
the tumor, it was also located in other tissues, while bLf was 
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found to be located only at the tumor site, with considerably 
bright contrast. Orally fed Fe-bLf NCs and Zn-Fe-bLf NCs 
gave a dark (T
2
) contrast, which could be seen to be present 
at the tumor site, as well as in the intestine. The Zn-Fe-bLf 
NCs were found to be dispersed around the tumor as well. 
A bright (T
1
) contrast was also observed in these mice, which 
could have been due to the presence of zinc. On the other 
hand, Fe-bLf NCs were highly localized in the tumor, and 
gave only T
2
 contrast (Figure 5A).
CT scans revealed a white contrast showing the presence 
of NCs, mainly in the body organs of the mice. The tumor 
was also seen clearly, and the contrast of Zn-Fe-bLf NCs 
was better than the Fe-bLf NCs. A higher intensity of Zn-Fe-
bLf NCs was observed in various organs in mice, indicating 
better uptake and clearly a better signal, suggesting that 
zinc incorporation may lead to improved signal intensity in 
imaging by CT scan (Figure 5B). Computerized tomographic 
studies conducted on Zn-Fe
3
O
4
 proved to be an efficient 
Table 1 Biodistribution pattern of fluorescent Zn-Fe-bLf NCs in 
cIMP1+/cIMP2−/cIN+ colonic adenocarcinoma and claudin-low, 
triple-negative (er−/Pr−/her2−) breast cancer mouse tissues
Sample Mouse organ Colon cancer  
mouse tissues
Breast cancer 
mouse tissues
1 Brain 1+ 1+
2 eyes – –
3 heart – 1+
4 spleen 3+ 2+
5 Kidneys 3+ 2+
6 lungs – 1+
7 Intestine 3+ 3+
8 liver 2+ 2+
9 Tumor 3+ 3+
10 Pancreas – 1+
11 Ovary – 1+
12 rectum – 1+
13 stomach 2+ 2+
14 spinal cord – 1+
Notes: –, Nil; 1+, low; 2+, medium; 3+, high.
Abbreviations: blf, bovine lactoferrin; Ncs, nanocapsules; cIMP, cpg-island 
methylator phenotype; cIN, chromosome instability.
Figure 5 In vivo magnetic resonance imaging and computerized tomography (cT) analysis.
Notes: (A) The upper panel reveals a T1 contrast of intratumorally injected Magnevist and blf. Magnevist was found to move to other tissues apart from the tumor location; 
however blf was located in the tumor and gave a better contrast. Both Fe3O4-saturated blf Ncs and Zn-Fe3O4-saturated blf Ncs gave a dark (T2) contrast in the tumor and 
around the intestines. (B) a bright contrast revealed presence of both Fe3O4-saturated blf Ncs and Zn-Fe3O4-saturated blf Ncs using the cT scans. Zn-Fe3O4 saturated blf 
was found to be better using cT. The untreated mice served as a control, with little or no contrast.
Abbreviations: blf, bovine lactoferrin; Ncs, nanocapsules.
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nanotheranostic approach in terms of better signal reception 
and crystal-clear imaging ability. Interestingly, Zn-Fe-bLf 
NCs proved to be effective multimodular nanotheranostic 
CT scanning agents, due to their therapeutic properties, and 
furthermore the observations correlated with earlier studies 
on Zn-Fe
3
O
4
 contrast agents.
Blood analysis for detection of calcium, zinc, and iron was 
performed along with analysis of red blood cell (RBC) and 
hematologic counts.6,7,35 As shown in Table 2, void NCs were 
able to insignificantly increase serum calcium, iron, and zinc 
concentrations, along with RBC count and hematologic count. 
However, Zn-Fe-bLf NCs led to a 1.31-fold (colon) and 1.40-
fold (breast) increase in serum calcium, while a 1.34-fold 
(colon) and 1.35-fold (breast) increase in serum iron was 
observed. The serum zinc level was also observed to increase 
by 1.81-fold (colon) and 1.85-fold (breast), while the RBC 
count increased by 1.88-fold (colon) and 1.80-fold (breast) 
and the total hematologic count was found to increase by 1.53-
fold (colon) and 1.77-fold (breast). Maintenance and control 
of iron homeostasis in cells is essential to prevent deficiency 
and toxicity of iron. As described in a previous publication,6 
the domain movements that close or open the iron-binding 
sites in the N- and C-lobes regulate the binding and release of 
iron by bLf. It was also found that a 1.2% (w/w) diet of Fe-
bLf raised iron levels from 0.0053% to just 0.0069%, which 
was statistically insignificant (P$0.05).6 In the present study, 
the majority of Zn-Fe-bLf was found to localize in the spleen 
and liver, away from the tumor. Since both these organs are 
capable of metabolizing the iron, there is no question of 
increase in metal-ion deposition. 
Using pharmacokinetic studies,7 we also showed that oral 
delivery of Fe-bLf ensured presence of Fe-bLf in 3 hours 
postfeeding, and Fe-bLf was not detectable beyond 72 hours, 
thus ensuring clearance of protein from the body. Current 
cancer treatments lead to anemia, due to such side effects 
as bleeding, hemolysis, deficiency of erythropoietic factors, 
gut infections, diarrhea, and other nutritional deficiencies.36,37 
In this study, we have shown clearly that Zn-Fe-bLf NCs 
substantially increased the serum iron, calcium, and zinc 
levels, RBC count, and hematologic count. We have already 
shown that bLf and Fe-bLf have immunomodulatory prop-
erties and lead to increase in iron, hemoglobin, and RBC 
counts.7,25 Therefore, Zn-Fe-bLf can also act as an alternative 
therapy for patients undergoing chemotherapy.38
Nude mice were used in the present study, mainly to study 
the tumor-suppression mechanism of Fe-bLf and not to study 
the immunomodulatory role. In a previous study, we have 
shown that Fe-bLf leads to increase in immunomodulatory 
cytokines.8 Therefore, these nanoparticles are capable of 
targeting cancer cells, as this was a nude mouse model, which 
is devoid of any immune cells. The anticancer mechanism 
of Fe-bLf has been provided in previous publications from 
our laboratory.8,10
Conclusion and future directions
In conclusion, the multifunctional nature of Zn-Fe-bLf NCs 
was noted in an in vivo human xenograft CIMP1+/CIMP2−/
CIN+ colonic adenocarcinoma and claudin-low, triple-
negative (ER−/PR−/HER2−) breast cancer model, leading 
to preferential downregulation of the tumor mass and 
also exhibiting safe, eco-friendly characteristics with the 
nontoxic and highly biocompatible nature of Zn-Fe-bLf 
NCs. The multimodular activity of the Zn-Fe-bLf NCs was 
monitored by NIR-fluorescence imaging, revealing a targeted 
nanotheranostic approach toward colon and breast cancer 
tumors. Future considerations for work in this area relate to 
uncover the in vivo anticancer-signaling and stem cell-sig-
naling mechanisms of Zn-Fe-bLf NCs in colon and breast 
tumors and improvisation of Zn-Fe-bLf NCs for enhancing 
selective therapeutic effects in combination with imaging 
strategies, such as ultrasound MRI, single photon-emission 
CT- and magnetic ultrasound-based imaging modalities.23,39–42 
Further, new technologies, such as aptamers, locked nucleic 
acid conjugates, and nanobodies are to be employed in a 
combinative treatment regime for the safe management of 
cancer therapies.4,43,44
Table 2 Serological profiling after Zn-Fe-bLf NC treatment in mice with colon and breast cancer
Elemental profiles Control Void NCs Zn-Fe-bLf NCs
Colon Breast Colon Breast Colon Breast
serum calcium (mg/dl) 6.36±2.21 5.7±1.73 6.85±1.61 6.63±2.07 8.38±0.84 8.03±1.60
serum iron (μg/g) 143±21 138±16 145±20 141±26 192±16 187±19
serum zinc (μg/dl) 7.78±1.48 8.01±3.15 9.16±2.11 9.47±0.89 14.10±2.83 14.86±1.73
rBc count 8.70±1.23 10.03±1.34 12.62±1.19 13.53±2.02 16.39±2.71 18.06±1.66
Total hematologic cell count 9.93±1.31 8.36±2.76 10.57±1.12 11.03±3.01 15.26±2.70 14.84±1.74
Note: Values expressed as mean ± standard deviation.
Abbreviations: blf, bovine lactoferrin; Nc, nanocapsule; rBc, red blood cell.
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Supplementary materials
Figure S1 Quantification of tumors by radiant efficiency of fluorescent signal in colon cancer model.
Notes: Near-infrared fluorescence imaging showed that Zn-Fe-bLf NCs exhibited a time-dependent downgrading pattern in colon tumor volume. Radiant efficiency of 
the fluorescent signal at the tumor site, area (in cm2) of the fluorescent signal at the tumor site, and area (in terms of CCD pixels) of the fluorescent signal at the tumor 
site were quantified to denote the decrease in tumor volume over the time period. Radiant efficiency presented as (A) area (cm2) and (B) area in terms of ccD pixels. 
(C) Tumor-reduction trend.
Abbreviations: blf, bovine lactoferrin; Ncs, nanocapsules; ccD, charge-coupled device.
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Figure S2 Quantification of tumors by radiant efficiency of fluorescent signal in breast cancer model.
Notes: A time-dependent, consistent decremental pattern in tumor volume was noted, as observed by in vivo near-infrared fluorescence imaging of Zn-Fe-bLf NCs. 
(A) Radiant efficiency; (B) area in terms of ccD-camera pixels; (C) consistent reduction pattern in tumor volume.
Abbreviations: blf, bovine lactoferrin; Ncs, nanocapsules; ccD, charge-coupled device.
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